SEARCH

SEARCH BY CITATION

References

  • 1
    Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 24756.
  • 2
    Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 8992.
  • 3
    Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 45361.
  • 4
    Barrett-Connor E. Fortnightly review: hormone replacement therapy. BMJ 1998; 317: 45761.
  • 5
    Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 60513.
  • 6
    Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 52334.
  • 7
    Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 170112.
  • 8
    Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. BJOG 2002; 109: 105662.
  • 9
    Post MS, Van Der Mooren MJ, Stehouwer CDA et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb Haemost 2002; 88: 60510.
  • 10
    Smolders RGV, Van Der Mooren MJ, Teerlink T et al. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels. Fertil Steril 2003; 79: 2617.
  • 11
    Post MS, Thomassen MCLGD, Van Der Mooren MJ et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 111621.
  • 12
    Vogelvang TE, Van Der Mooren MJ, Kamp O, Mijatovic V, Visser CA, Kenemans P. Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function. Fertil Steril 2003; 80: 54653.
  • 13
    Post MS, Van Der Mooren MJ, Van Baal WM et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003; 189: 12217.
  • 14
    Hemelaar M, Van Der Mooren MJ, Mijatovic V et al. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study. Menopause 2003; 10: 5508.
  • 15
    Post MS, Leurs JR, Van Der Mooren MJ et al. Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study. Thromb Haemost 2005; 93: 6202.
  • 16
    Hemelaar M, Van Der Mooren MJ, Van Baal WM, Schalkwijk CG, Kenemans P, Stehouwer CDA. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause 2005; 12: 52635.
  • 17
    Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(Suppl 12): S602.
  • 18
    Valkonen VP, Päivä H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 21278.
  • 19
    Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 21137.
  • 20
    Nijveldt RJ, Teerlink T, Van Der Hoven B et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 2330.
  • 21
    Li XP, Zhou Y, Zhao SP, Gao M, Zhou QC, Li YS. Effect of endogenous estrogen on endothelial function in women with coronary heart disease and its mechanism. Clin Chim Acta 2004; 339: 1838.
  • 22
    Post MS, Verhoeven MO, Van Der Mooren MJ, Kenemans P, Stehouwer CDA, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003; 88: 42216.
  • 23
    Teerlink T, Neele SJM, de Jong S, Netelenbos JC, Stehouwer CDA. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003; 105: 6771.
  • 24
    Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001; 75: 898915.
  • 25
    Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598603.
  • 26
    Teerlink T, Nijveldt RJ, de Jong S, Van Leeuwen PAM. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 1317.
  • 27
    Foster RH, Balfour JA. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging 1997; 11: 30932.
  • 28
    Lemus AE, Jaimez R, Lemini C et al. Estrogenic effects of the synthetic aminoestrogen 17 beta-(5-hydroxy-1-pentylamino)-1,3,5(10)-estratrien-3-ol (pentolame). Steroids 1998; 63: 4338.
  • 29
    Lundeen SG, Zhang Z, Zhu Y, Carver JM, Winneker RC. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001; 78: 13743.
  • 30
    Achan V, Broadhead M, Malaki M et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 14559.
  • 31
    Murray-Rust J, Leiper J, McAlister M et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001; 8: 67983.
  • 32
    Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 256975.
  • 33
    Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 30925.
  • 34
    Dai Z, Zhu HQ, Jiang DJ, Jiang JL, Deng HW, Li YJ. 17beta-estradiol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Int J Cardiol 2004; 96: 2237.
  • 35
    Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003; 108: 157580.
  • 36
    Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001; 100: 1617.
  • 37
    Stühlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003; 108: 9338.
  • 38
    Wanby P, Brattström L, Brudin L, Hultberg B, Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest 2003; 63: 34753.
  • 39
    Doshi S, McDowell I, Goodfellow J et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 2005; 54: 35160.
  • 40
    Nijveldt RJ, Teerlink T, Siroen MPC, Van Lambalgen AA, Rauwerda JA, Van Leeuwen PAM. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003; 22: 1722.
  • 41
    Siroen MPC, Warle MC, Teerlink T et al. The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl 2004; 10: 152430.